Impacts of anti-drug antibodies on pharmacokinetic and pharmacodynamic actions of cell-permeable middle molecule peptide drug.

IF 3.8 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Mengxuan Gao, Ryota Saito, Hiroo Watanabe, Tomofumi Shimojo, Taichi Akahoshi, Shino Kuramoto, Tatsuhiko Tachibana
{"title":"Impacts of anti-drug antibodies on pharmacokinetic and pharmacodynamic actions of cell-permeable middle molecule peptide drug.","authors":"Mengxuan Gao, Ryota Saito, Hiroo Watanabe, Tomofumi Shimojo, Taichi Akahoshi, Shino Kuramoto, Tatsuhiko Tachibana","doi":"10.1016/j.jpet.2025.103663","DOIUrl":null,"url":null,"abstract":"<p><p>The administration of peptide drugs can induce the generation of anti-drug antibodies (ADAs), potentially leading to unwanted effects such as reduced drug efficacy, which is often seen with therapeutic monoclonal antibodies. However, the influence of ADAs on the pharmacokinetic and pharmacodynamic properties of cell-permeable middle molecules remains unclear. This study investigated ADA impacts using AP2151, a middle molecule cyclic peptide with high cell membrane permeability. ADAs were generated by immunizing rabbits with an AP2151 analog conjugated to keyhole limpet hemocyanin. A dialysis experiment was then performed to determine the binding affinity between AP2151 and the purified ADAs. Using in-house experimental data, we established a SimBiology model to simulate the pharmacokinetic profiles of AP2151 in varying ADA concentrations. The simulation results suggested that higher ADA levels (up to several micromolar) would more strongly increase the total plasma concentrations of AP2151 without apparently changing the free concentrations. Thus, according to the free drug theory, the pharmacological effect was predicted to remain constant despite the presence of ADAs. These predictions were subsequently confirmed by an in vivo study, in which mice were administered with AP2151 following a preliminary infusion with or without ADAs. Our findings suggest that in the case of cell-permeable middle molecules, ADAs raise total drug concentrations but have little impact on the drug efficacy. SIGNIFICANCE STATEMENT: We conducted both model-based simulation and in vivo experiments to examine anti-drug antibody impacts on a cell-permeable middle molecule drug. As predicted by the model and confirmed by mouse studies, the presence of anti-drug antibodies increases the total plasma concentration of the drug without compromising its pharmacological effects, highlighting the significance of model analysis and may contribute to the understanding of middle molecule compounds.</p>","PeriodicalId":16798,"journal":{"name":"Journal of Pharmacology and Experimental Therapeutics","volume":"392 9","pages":"103663"},"PeriodicalIF":3.8000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology and Experimental Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jpet.2025.103663","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The administration of peptide drugs can induce the generation of anti-drug antibodies (ADAs), potentially leading to unwanted effects such as reduced drug efficacy, which is often seen with therapeutic monoclonal antibodies. However, the influence of ADAs on the pharmacokinetic and pharmacodynamic properties of cell-permeable middle molecules remains unclear. This study investigated ADA impacts using AP2151, a middle molecule cyclic peptide with high cell membrane permeability. ADAs were generated by immunizing rabbits with an AP2151 analog conjugated to keyhole limpet hemocyanin. A dialysis experiment was then performed to determine the binding affinity between AP2151 and the purified ADAs. Using in-house experimental data, we established a SimBiology model to simulate the pharmacokinetic profiles of AP2151 in varying ADA concentrations. The simulation results suggested that higher ADA levels (up to several micromolar) would more strongly increase the total plasma concentrations of AP2151 without apparently changing the free concentrations. Thus, according to the free drug theory, the pharmacological effect was predicted to remain constant despite the presence of ADAs. These predictions were subsequently confirmed by an in vivo study, in which mice were administered with AP2151 following a preliminary infusion with or without ADAs. Our findings suggest that in the case of cell-permeable middle molecules, ADAs raise total drug concentrations but have little impact on the drug efficacy. SIGNIFICANCE STATEMENT: We conducted both model-based simulation and in vivo experiments to examine anti-drug antibody impacts on a cell-permeable middle molecule drug. As predicted by the model and confirmed by mouse studies, the presence of anti-drug antibodies increases the total plasma concentration of the drug without compromising its pharmacological effects, highlighting the significance of model analysis and may contribute to the understanding of middle molecule compounds.

抗药抗体对细胞渗透性中间分子多肽药物的药动学和药效学作用的影响。
多肽药物的施用可以诱导抗药物抗体(ADAs)的产生,潜在地导致不良影响,如药物疗效降低,这在治疗性单克隆抗体中经常看到。然而,ADAs对细胞渗透性中间分子的药代动力学和药效学特性的影响尚不清楚。本研究利用具有高细胞膜通透性的中间分子环肽AP2151研究ADA的影响。将AP2151类似物与锁孔帽贝血青素偶联免疫家兔产生ADAs。然后进行透析实验以确定AP2151与纯化的ADAs之间的结合亲和力。利用内部实验数据,我们建立了SimBiology模型来模拟不同ADA浓度下AP2151的药代动力学特征。模拟结果表明,较高的ADA浓度(高达几个微摩尔)会更强烈地增加AP2151的总血浆浓度,而不会明显改变游离浓度。因此,根据游离药物理论,尽管存在ADAs,其药理作用预计仍将保持不变。这些预测随后被一项体内研究证实,在该研究中,小鼠在初步输注ADAs或不输注ADAs后给予AP2151。我们的研究结果表明,在具有细胞渗透性的中间分子的情况下,ADAs提高了药物总浓度,但对药物疗效的影响很小。意义声明:我们通过模型模拟和体内实验来研究抗药物抗体对细胞渗透性中间分子药物的影响。正如模型预测和小鼠研究证实的那样,抗药物抗体的存在增加了药物的总血浆浓度,而不影响其药理作用,突出了模型分析的重要性,并可能有助于理解中间分子化合物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
115
审稿时长
1 months
期刊介绍: A leading research journal in the field of pharmacology published since 1909, JPET provides broad coverage of all aspects of the interactions of chemicals with biological systems, including autonomic, behavioral, cardiovascular, cellular, clinical, developmental, gastrointestinal, immuno-, neuro-, pulmonary, and renal pharmacology, as well as analgesics, drug abuse, metabolism and disposition, chemotherapy, and toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信